SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals

Nils C. Gassen, Jan Papies, Thomas Bajaj, Jackson Emanuel, Frederik Dethloff, Robert Lorenz Chua, Jakob Trimpert, Nicolas Heinemann, Christine Niemeyer, Friderike Weege, Katja Hönzke, Tom Aschman, Daniel E. Heinz, Katja Weckmann, Tim Ebert, Andreas Zellner, Martina Lennarz, Emanuel Wyler, Simon Schroeder, Anja Richter, Daniela Niemeyer, Karen Hoffmann, Thomas F. Meyer, Frank L. Heppner, Victor M. Corman, Markus Landthaler, Andreas C. Hocke, Markus Morkel, Nikolaus Osterrieder, Christian Conrad, Roland Eils, Helena Radbruch, Patrick Giavalisco, Christian Drosten, Marcel A. MüllerNature Communications 2021 · DOI

Abstract

Viruses manipulate cellular metabolism and macromolecule recycling processes like autophagy. Dysregulated metabolism might lead to excessive inflammatory and autoimmune responses as observed in severe and long COVID-19 patients. Here we show that SARS-CoV-2 modulates cellular metabolism and reduces autophagy. Accordingly, compound-driven induction of autophagy limits SARS-CoV-2 propagation. In detail, SARS-CoV-2-infected cells show accumulation of key metabolites, activation of autophagy inhibitors (AKT1, SKP2) and reduction of proteins responsible for autophagy initiation (AMPK, TSC2, ULK1), membrane nucleation, and phagophore formation (BECN1, VPS34, ATG14), as well as autophagosome-lysosome fusion (BECN1, ATG14 oligomers). Consequently, phagophore-incorporated autophagy markers LC3B-II and P62 accumulate, which we confirm in a hamster model and lung samples of COVID-19 patients. Single-nucleus and single-cell sequencing of patient-derived lung and mucosal samples show differential transcriptional regulation of autophagy and immune genes depending on cell type, disease duration, and SARS-CoV-2 replication levels. Targeting of autophagic pathways by exogenous administration of the polyamines spermidine and spermine, the selective AKT1 inhibitor MK-2206, and the BECN1-stabilizing anthelmintic drug niclosamide inhibit SARS-CoV-2 propagation in vitro with IC<sub>50</sub> values of 136.7, 7.67, 0.11, and 0.13 μM, respectively. Autophagy-inducing compounds reduce SARS-CoV-2 propagation in primary human lung cells and intestinal organoids emphasizing their potential as treatment options against COVID-19.

Introduction

Viruses are the ultimate metabolic hijackers. To replicate, they must reprogram the host cell to provide a steady stream of energy and molecular building blocks, such as amino acids, lipids, and nucleotides. A critical part of cellular maintenance is autophagy, a process where cells capture damaged components or invading pathogens in vesicles called autophagosomes and fuse them with lysosomes for degradation. While some viruses utilize autophagy components to build replication factories, others actively suppress it to avoid degradation. This study investigates how SARS-CoV-2 manipulates these pathways and whether restoring cellular recycling can serve as a host-targeting antiviral strategy.

Methods

The researchers employed a multi-omic, cross-species approach to map the effects of SARS-CoV-2 infection:

  • Metabolomics: Targeted metabolic profiling on VeroFM (monkey kidney) and Calu-3 (human lung) cells to identify shifts in central carbon metabolism.
  • Functional Autophagy Assays: Tracking autophagosome formation and fusion using Western blotting and fluorescence microscopy (mRFP-EGFP-LC3B reporter).
  • Transcriptomics: Analysis of single-cell and single-nucleus RNA sequencing data from COVID-19 patient mucosal brushes and post-mortem lung samples.
  • Validation Models: Findings were confirmed in Syrian hamsters, primary human airway epithelial cells (AEC), and human intestinal organoids.
  • Drug Screening: Testing of autophagy-inducing compounds, including polyamines (spermidine/spermine), the AKT1 inhibitor MK-2206, and niclosamide.

Results

Metabolic Reprogramming and the "Metabolic Glut"

Infected cells exhibit a massive accumulation of amino acids and nucleotides. This is not merely a byproduct; the virus triggers a translational shutoff of host proteins while accelerating the ubiquitin-proteasome system to create a resource pool for viral assembly. Metabolomic analysis across different cell lines confirmed significant enrichment in pathways related to amino acid metabolism and nucleotide synthesis.

The Autophagy Fusion Blockade

SARS-CoV-2 does not prevent autophagosomes from forming; instead, it prevents them from fusing with lysosomes. This results in an accumulation of "clogged" autophagosomes, marked by high levels of LC3B-II and P62 proteins. This blockade was confirmed in lab models, infected hamsters, and lung samples from human COVID-19 victims.

Metabolic and autophagy dysregulation overview showing pathway enrichment and molecular mechanisms.

Molecular Sabotage of Autophagy

The virus actively suppresses autophagy through the AKT1/SKP2 pathway. Activation of AKT1 leads to the activation of SKP2, which then targets Beclin-1 (BECN1)—a master regulator of autophagy—for degradation. Simultaneously, the virus reduces the activity of AMPK and ULK1, the primary "on-switches" for autophagy initiation.

Potent Inhibition via Autophagy Induction

Because the virus relies on suppressing this host pathway, drugs that stabilize BECN1 or inhibit the AKT1/SKP2 axis can "unlock" the autophagy process. Several compounds showed strong antiviral activity in vitro:

  • MK-2206 (AKT1 inhibitor): IC<sub>50</sub> of 0.11 μM.
  • Niclosamide (BECN1 stabilizer): IC<sub>50</sub> of 0.13 μM.
  • Spermine/Spermidine: IC<sub>50</sub> of 7.67 μM and 136.7 μM, respectively.

These compounds significantly reduced viral propagation in complex human intestinal organoids and primary human lung cells, demonstrating high translational potential.

Discussion

While these findings highlight promising therapeutic targets, several challenges remain. Niclosamide is highly potent but has poor systemic absorption, suggesting that inhalable formulations might be necessary for lung delivery. Furthermore, while spermidine concentrations required for inhibition are high, intracellular levels can be boosted by supplementation. Future work is needed to identify the specific viral proteins interacting with the AKT1/SKP2 pathway and to conduct clinical trials to determine the optimal timing for autophagy induction in COVID-19 patients.

Summary updated

Abstract

Viruses manipulate cellular metabolism and macromolecule recycling processes like autophagy. Dysregulated metabolism might lead to excessive inflammatory and autoimmune responses as observed in severe and long COVID-19 patients. Here we show that SARS-CoV-2 modulates cellular metabolism and reduces autophagy. Accordingly, compound-driven induction of autophagy limits SARS-CoV-2 propagation. In detail, SARS-CoV-2-infected cells show accumulation of key metabolites, activation of autophagy inhibitors (AKT1, SKP2) and reduction of proteins responsible for autophagy initiation (AMPK, TSC2, ULK1), membrane nucleation, and phagophore formation (BECN1, VPS34, ATG14), as well as autophagosome-lysosome fusion (BECN1, ATG14 oligomers). Consequently, phagophore-incorporated autophagy markers LC3B-II and P62 accumulate, which we confirm in a hamster model and lung samples of COVID-19 patients. Single-nucleus and single-cell sequencing of patient-derived lung and mucosal samples show differential transcriptional regulation of autophagy and immune genes depending on cell type, disease duration, and SARS-CoV-2 replication levels. Targeting of autophagic pathways by exogenous administration of the polyamines spermidine and spermine, the selective AKT1 inhibitor MK-2206, and the BECN1-stabilizing anthelmintic drug niclosamide inhibit SARS-CoV-2 propagation in vitro with IC<sub>50</sub> values of 136.7, 7.67, 0.11, and 0.13 μM, respectively. Autophagy-inducing compounds reduce SARS-CoV-2 propagation in primary human lung cells and intestinal organoids emphasizing their potential as treatment options against COVID-19.
BibTeX
@inproceedings{gassen2021sars,
  author = {Nils C. Gassen and Jan Papies and Thomas Bajaj and Jackson Emanuel and Frederik Dethloff and Robert Lorenz Chua and Jakob Trimpert and Nicolas Heinemann and Christine Niemeyer and Friderike Weege and Katja Hönzke and Tom Aschman and Daniel E. Heinz and Katja Weckmann and Tim Ebert and Andreas Zellner and Martina Lennarz and Emanuel Wyler and Simon Schroeder and Anja Richter and Daniela Niemeyer and Karen Hoffmann and Thomas F. Meyer and Frank L. Heppner and Victor M. Corman and Markus Landthaler and Andreas C. Hocke and Markus Morkel and Nikolaus Osterrieder and Christian Conrad and Roland Eils and Helena Radbruch and Patrick Giavalisco and Christian Drosten and Marcel A. Müller},
  title = {{SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals}},
  booktitle = {Nature Communications},
  year = {2021},
  doi = {10.1038/s41467-021-24007-w},
}
Figure